|Clinical Trial Title||Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer|
|Trial Status||Closed to Enrollment|
|Location||Doctors & Locations|
|Trial Type||Cancer - Adult Oncology|
|Specific Condition||Breast Cancer|
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer.
PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.
SWOG S1207: Breast Cancer Trial
ü ER and/or PR positive
ü Must have completed either adjuvant or neoadjuvant chemotherapy
|Principal Investigator||Jacqueline Vuky, MD|
|Contact Name||Legacy Oncology Clinical Research|